Response and Resistance to BCR-ABL1-Targeted Therapies - ScienceDirect
Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group | Modern Pathology
Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms | Published in healthbook TIMES Oncology Hematology
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Cancers | Free Full-Text | Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Low prevalence of the BCR–ABL1 fusion gene in a normal population in southern Sarawak | SpringerLink
Persistence of LSCs: BCR-ABL1 kinase-dependent and -independent pathways. | Download Scientific Diagram
Change in BCR-ABL1 IS over time based on achievement of BCR-ABL1 IS 10%... | Download Scientific Diagram
BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? - Chiaretti - 2019 - Cancer - Wiley Online Library
Frontiers | Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
Cancers | Free Full-Text | Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
The Philadelphia chromosome in leukemogenesis | Cancer Communications | Full Text
Pharmaceutics | Free Full-Text | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia | NEJM
The role of BCR-ABL1 in the genomic instability. High levels of... | Download Scientific Diagram
Frontiers | A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs
The Philadelphia chromosome in leukemogenesis | Cancer Communications | Full Text
Frontiers | Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update
Measurable residual disease in chronic myeloid leukemia | Haematologica
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia
Response and Resistance to BCR-ABL1-Targeted Therapies - ScienceDirect
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib? – ScienceOpen
Characterization and monitoring by droplet digital PCR of a novel BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques | PLOS ONE
Structure of the BCR/ABL1 oncogene. (A) Schematic representation of the... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission | Leukemia
IJMS | Free Full-Text | Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?
Cancers | Free Full-Text | Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
IVD Antibody Development Services for BCR-ABL Marker - Creative Biolabs
